注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
BriaCell Therapeutics Corp是一家免疫肿瘤生物技术公司。该公司专注于开发增强人体自身抗癌细胞摧毁癌性肿瘤能力的疗法。其主要候选药物Bria-IMT是一种靶向免疫疗法,正在开发用于治疗晚期乳腺癌。该公司专注于进行Bria-IMT的I/IIa期临床试验,与免疫检查点抑制剂,如与Incyte药物retifanlimab、抗 PD-1抗体如pembrolizumab和epacadostat等进行联合研究。Bria-IMT是一种基因工程改造的人乳腺癌细胞系,具有免疫细胞的特性,在临床上用作靶向免疫治疗。该公司还专注于开发Bria-OTS,这是一种针对乳腺癌的现成个性化免疫疗法以及针对其他癌症适应症的类似免疫疗法细胞系。Bria-OTS免疫疗法基于患者的HLA类型。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Martin E. Schmieg | 61 | 2020 | Independent Director |
Charles Louis Wiseman | 77 | 2014 | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
Brian W. Metcalf | 77 | 2017 | Member of Scientific Advisory Board |
Douglas V. Faller | - | 2017 | Member of Scientific Advisory Board |
Maria Trojanowska | - | 2017 | Member of Scientific Advisory Board |
Vaughn C. Embro-Pantalony | 67 | 2019 | Lead Independent Director |
William V. Williams | 67 | 2016 | CEO, President & Director |
Thomas Kieber-Emmons | - | 2017 | Member of Scientific Advisory Board |
Jamieson Bondarenko | 37 | 2019 | Independent Chairman of the Board |
Cara L. Haymaker | - | 2019 | Member of Scientific Advisory Board |
Rebecca A. Taub | 71 | 2019 | Independent Director |
Alexander Kharazi | - | 2022 | Member of Scientific Advisory Board |
Massimo Cristofanilli | - | 2023 | Member of Medical Advisory Board |
Jane A. Gross | 66 | 2021 | Independent Director |
Adam M. Brufsky | - | 2023 | Member of Medical Advisory Board |
Suzanne Ostrand-Rosenberg | - | 2021 | Member of Scientific Advisory Board |
Sara A. Hurvitz | - | 2023 | Member of Medical Advisory Board |
Charles Sidman | - | 2023 | Member of Scientific Advisory Board |
Marc Lustig | 50 | 2021 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核